Read More

Palvella Therapeutics And Ligand Pharmaceuticals Expand Strategic Partnership To Accelerate Phase 3 Development Of QTORIN Rapamycin For Microcystic Lymphatic Malformations And Additional High Unmet Need Clinical Indications; Palvella Received $5M Payme…

Palvella Received $5 Million Upfront Payment QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients with

LGND

Read More

City Of New Orleans Chooses Samsara’s Connected Operations Cloud Across 41 Departments; The City Is Investing $75M In Its Fleet And Views The Technology Partnership With Samsara As Critical For Maintaining And Protecting Its Vehicles As Well As The Pub…

Samsara Inc. ("Samsara") (NYSE:IOT), the pioneer of the Connected Operations™ Cloud, today announced that the City of New Orleans will use Samsara's technology to improve the safety, efficiency, and sustainability

IOT